Other
NMIBC
2
Pipeline Programs↗
6
Active Trials↗
5
Companies Involved↗
NMIBC is an early-stage landscape with 2 programs across 5 companies. The most active players are Tyra Biosciences, Inc, Lindis Biotech GmbH, Anchiano Therapeutics Israel Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
10
clinical trials
Recruiting3 · 30%
Not yet recruiting2 · 20%
Unknown status1 · 10%
Withdrawn1 · 10%
Active, not recruiting1 · 10%
Terminated1 · 10%
Other1 · 10%
Clinical Trials
Trial Activity
10 trials
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Not yet recruiting·—·Phase 2·NCT07322263·174 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)